About
We are a clinical-stage biopharmaceutical company developing new drugs for cardiovascular diseases.
Founded by cardiologists and backed by renowned Los Angeles hospital Cedars-Sinai, our aim is to make significant advances in the treatment of cardiovascular diseases by addressing mechanisms of inflammation that drive pathogenesis. This has been a core area of research of our founding scientists for 30 years.
We develop biologic therapies for patients with significant unmet medical need. Our pipeline focuses on treating atherosclerotic cardiovascular disease, inflammation, and cardiometabolic dysfunction in patients with psoriasis. We also working to create therapies for patients at risk of cardiovascular complications from lipoprotein(a). Neither condition has an approved therapy.
Our committed team of scientists and drug developers bring decades of therapeutics development experience and a track-record of success to the Company.
Board of Directors
JOHN FARINA
Managing Director, Glenbarr Partners
WILLEM MESDAG
Managing Director, Red Mountain Capital
EDWARD M. PRUNCHUNAS
Chief Financial Officer, Cedars-Sinai Medical Center
PREDIMAN K. SHAH, M.D.
Director and Founder, Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center
JAN NILSSON, M.D., PHD
Chairman, Clinical Research Center, Lund University
TIMOTHY WRIGHT, M.D.
General Partner, Time Bioventures
Strategic Advisers
D.A. WALLACH
KARAN BILIMORIA
Investors
Our Pipeline
Our pipeline focuses on patient populations at high-risk of cardiometabolic complications from underlying chronic inflammation.
